Melanoma Cell Growth Inhibited by Novel Compound
News Jan 04, 2018 | by Laura Elizabeth Mason, Science Writer, Technology Networks
Cancer Cell Among 'Normal' Cells
Through a collaborative effort, researchers have developed a novel compound with the ability to inhibit melanoma cell growth. This research, published today in Nature Communications, could pave the way for the development of a new class of cancer therapies, with improved safety and efficacy.
The term ‘epigenetics’ is used to define the molecular processes that influence changes in gene expression, without directly affecting the original DNA sequence. The body is able to turn genes ‘on’ or ‘off’ via epigenetic changes. These changes can result in cellular modifications that can lead to the conversion of a cell from ‘normal’ to ‘cancerous’, and can also promote a tumor’s growth and resistance to treatment.
The novel compound ‘Corin’ can target specific epigenetic modifying proteins. Through this mechanism, it could be possible to significantly improve a patient’s condition, without unwanted adverse effects. The clinical use of epigenetic drugs is currently limited due to their limited therapeutic window and unexpected adverse effects. Corin’s dual-target specificity makes it an attractive inhibitor of epigenetic modifications, as it enables selective targeting of epigenetic complexes, more specifically, it inhibits cellular demethylase and deacetylase activity.
Co-corresponding author Rhoda M. Alani, MD, Boston University School of Medicine (BUSM), commented on the potential impact of their findings in a recent press release: "It is anticipated that this novel compound will have significant efficacy in human melanomas and other cancers either as a stand-alone therapy or in combination with other targeted or immune-based therapies,"
The researchers used a melanoma cell culture system to assess the efficacy of Corin, and determined that several cancer-associated activities; cellular growth, differentiation and migration, were affected in vitro. Additional experimental melanoma models demonstrated that the compound could inhibit tumor cell growth with nominal toxicity.
The team noted that the effectiveness of targeted epigenetic therapies may not be confined to the oncology field, as epigenetic changes are also known to affect the immune system.
Alani concluded: "It is expected that this study will lay the foundation for developing a new class of potent and effective cancer therapies and the development of reagents targeting epigenetic events in immune-mediated diseases as well as other epigenetically-influenced diseases."
Auto Industry Tip Improves Smoked FoodNews
Infusing foods with smoke can impart delicious flavors, but could also come with an unwelcome side of carcinogens. To reduce the carcinogen content of smoked foods, researchers took a lesson from the automobile industry, running the smoke through a zeolite filter to remove harmful compounds. It worked, and with a happy bonus: superior smoke flavor.READ MORE
Test For Designer Drugs Could Help Treat Overdose PatientsNews
Medical professionals are scrambling to meet the growing demand for emergency room treatment, but they’re hampered by the lack of a quick and easy test to screen patients for “designer” drugs. Chemists have now developed such a test and are refining it with the hope that hospitals could eventually use it to choose the appropriate treatment.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018